Back to Journals » OncoTargets and Therapy » Volume 10

Primary neuroendocrine breast carcinomas: a retrospective analysis and review of literature

Authors Yang X, Cao YD, Chen C, Liu L, Wang C, Liu SC

Received 27 May 2016

Accepted for publication 2 September 2016

Published 18 January 2017 Volume 2017:10 Pages 397—407

DOI https://doi.org/10.2147/OTT.S113736

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Jia Fan

Peer reviewer comments 3

Editor who approved publication: Dr Ingrid Espinoza

Xin Yang,1 Youde Cao,2 Chen Chen,1 Lin Liu,1 Cheng Wang,1 Shengchun Liu1

1Department of Endocrine and Breast Surgery, The First Affiliated Hospital of Chongqing Medical University, 2Department of Pathology, Chongqing Medical University, Chongqing, People’s Republic of China


Background: Primary neuroendocrine breast carcinomas (NEBCs) are a rare type of breast carcinomas that lack comprehensive recognition, including the clinicopathological features, therapeutic strategies, and prognostic significance. The aim of this retrospective analysis is to present and analyze our own data of primary NEBCs.
Materials and methods: We retrospectively reviewed the medical records from 2005 to 2015 in The First Affiliated Hospital of Chongqing Medical University, Chongqing, People’s Republic of China to obtain a cohort of breast carcinoma patients who were confirmed to have primary NEBC by histopathology. The detailed clinical data along with histopathology, treatment, and follow-up aspects were gathered for analysis.
Results: This retrospective analysis included 19 patients with a histopathological diagnosis of primary NEBC from 2005 to 2015. Their mean age was 59.2 years (ranging from 17 to 82 years). The majority of patients (15/19) focused on stages I and II. Of the 15 patients, 14 were positive for estrogen receptor, and 11 were positive for progesterone receptor. For neuroendocrine markers, the expression rates were 8/19, 14/18, 12/14, and 2/6 for chromogranin A, synaptophysin, neuron-specific enolase, and CD56, respectively. All operable patients except the one stage M1 underwent a surgery and 4/18 had axillary lymph node metastasis. Chemotherapy was performed in 12/19, and endocrine therapy in 8/10. With a median follow-up of 59.2 months, only 2 cases progressed after postoperative systemic therapy.
Conclusion: The understanding of NEBC is limited due to its rarity. More evidence should be provided to enhance the understanding of NEBC, especially for diagnosis, treatment, and prognosis.

Keywords: primary neuroendocrine breast carcinomas, diagnosis, therapy, follow-up

Corrigendum for this paper has been published.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other article by this author:

Primary neuroendocrine breast carcinomas: a retrospective analysis and review of literature [Corrigendum]

Yang X, Cao YD, Chen C, Liu L, Wang C, Liu SC

OncoTargets and Therapy 2017, 10:1707-1708

Published Date: 21 March 2017